We also identified MARCO as TAM‐enriched inhibitor of neoantigen cross‐presentation in ICB‐resistant RCCs, and demonstrated the therapeutic efficacy of targeting MARCO to recover tumor recognition and generate effective antitumor immunity in the ICB non‐responsive malignancies otherwise. This evidence concerns the gene MARCO and neoplasm.